Wave Life Sciences reported on Monday that a single dose of its injectable RNA treatment, WVE-007, led to a 4% reduction in total body fat after approximately three months. This announcement comes from interim data collected during the ongoing Phase I INLIGHT trial.
The company detailed that, after adjusting for placebo effects, the lowest therapeutic dose of WVE-007 resulted in a 9.2% reduction in visceral fat and a 0.9% increase in lean mass. No statistically significant changes were observed in participants who received the placebo.
Analysts at Truist described the results as “impressive,” stating: “Bottomline, in our view, update today from WVE-007 fundamentally changes the outlook for obesity landscape in a very disruptive manner and for the better.” The analysts noted that these findings are promising ahead of longer-term data expected in the first quarter of 2026. They also highlighted that maintaining lean mass is an advantage over other weight loss therapies such as GLP-1s, which often lead to muscle loss.
Shares of Wave increased by 80%, reaching $13.52 during Monday morning trading.
Mizuho Group analysts called the interim data “very positive” and estimated peak sales for WVE-007 could reach about $7 billion if approved. They compared WVE-007’s performance to Novo Nordisk’s semaglutide—marketed as Wegovy for weight loss and Ozempic for diabetes—noting that semaglutide showed only 2–2.5% fat loss at twelve weeks along with a decrease in lean mass by 3.5%. In contrast, WVE-007’s effects occurred without any lifestyle modifications or gastrointestinal side effects commonly associated with GLP-1s; no discontinuations or serious adverse events were reported in this Phase I trial. The Mizuho analysts wrote: “Safety looks very clean.”
Wave plans to release additional data in early 2026, including six-month results for the lowest dose (240 mg), as well as three-month and six-month data for higher doses (400 mg and 600 mg).
WVE-007 is an injectable RNAi therapy designed to silence mRNA encoding the INHBE protein. According to Wave Life Sciences, individuals with a specific mutation causing reduced function of one copy of their INHBE gene tend to have healthier body composition and improved cardiometabolic health.
